Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Accumulated Expenses (2019 - 2025)

China Pharma Holdings (CPHI) has disclosed Other Accumulated Expenses for 7 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses rose 6614.61% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Sep 2025, up 6614.61%, and an annual FY2024 reading of $1.6 million, up 26.44% over the prior year.
  • Other Accumulated Expenses was $1.6 million for Q3 2025 at China Pharma Holdings, roughly flat from $1.6 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.1 million in Q3 2021 and bottomed at $24000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 5 years is $2.0 million, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses tumbled 97.84% in 2024, then soared 6614.61% in 2025.
  • Year by year, Other Accumulated Expenses stood at $2.8 million in 2021, then decreased by 10.93% to $2.5 million in 2022, then crashed by 49.29% to $1.3 million in 2023, then rose by 26.44% to $1.6 million in 2024, then rose by 1.51% to $1.6 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CPHI at $1.6 million in Q3 2025, $1.6 million in Q2 2025, and $1.6 million in Q1 2025.